Melanotan-1 · Research brief

Melanotan-1 Benefits — Research Applications | Real Peptides

Real Peptides Research TeamEditorial

Updated March 26, 202613 min read

41 WORDS

Short answer

Key takeaways

Melanotan-1 exhibits 100–1000× selectivity for MC1R over MC3R and MC4R in competitive binding assays, allowing researchers to isolate melanogenesis effects without confounding appetite or metabolic variables.
MC1R activation by Melanotan-1 triggers the cAMP-PKA-CREB-MITF-tyrosinase cascade, increasing melanin synthesis 300–500% above baseline UV-stimulated levels in cultured melanocyte studies.
Photoprotection conferred by Melanotan-1-induced melanogenesis increases minimal erythema dose by 2.0–2.8× in fair-skinned subjects, measured as UV exposure tolerance before visible redness appears.
Lyophilized Melanotan-1 remains stable for 24–36 months at −20°C; once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28–45 days before degradation exceeds 5%.
Temperature excursions above 25°C or mechanical agitation during reconstitution denature peptide structure, eliminating MC1R binding activity regardless of amino acid sequence integrity.
The single amino acid substitution (norleucine at position 9) extends Melanotan-1 half-life from minutes to 2.5–3.5 hours by preventing peptidase degradation while preserving MC1R pharmacophore structure.

A 2022 systematic review published in the Journal of Investigative Dermatology found that alpha-MSH analogs like Melanotan-1 demonstrated melanogenesis induction rates 300–500% higher than baseline UV-stimulated pathways in cultured melanocytes. That's not incremental improvement—that's a fundamentally different biological pathway being activated. We've supplied research-grade peptides to laboratories studying melanocortin receptor pharmacology for years, and the gap between what marketing materials claim and what peer-reviewed receptor binding assays actually show is substantial.

What are the benefits of Melanotan-1 in research contexts?

Melanotan-1 benefits include selective MC1R agonism for melanogenesis studies, reduced off-target melanocortin receptor binding compared to MT2, photoprotection mechanism research without confounding appetite or libido effects, and stable peptide structure for controlled dosing protocols. The peptide's alpha-MSH analog structure provides researchers with a tool to isolate MC1R-mediated effects from the broader melanocortin system.

Melanotan-1 isn't just "the other tanning peptide." Its receptor selectivity profile makes it fundamentally different from Melanotan-2 in ways that matter for research design. MT1 demonstrates 10–100 fold selectivity for MC1R over MC3R/MC4R in competitive binding assays, meaning studies examining melanogenesis pathways face fewer confounding variables from appetite suppression or erectile function changes. This article covers the specific melanocortin-1 benefits that distinguish it in peptide research, the receptor pharmacology that creates those distinctions, and what preparation errors eliminate peptide activity entirely before the first injection.

Melanocortin Receptor Selectivity and MC1R Agonism

Melanotan-1 operates as a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous peptide that binds melanocortin receptors throughout the body. The melanocortin system includes five receptor subtypes (MC1R through MC5R), each mediating distinct physiological functions. MC1R, expressed primarily on melanocytes in the skin and hair follicles, regulates eumelanin and pheomelanin synthesis—the pigments responsible for skin and hair color. MC3R and MC4R, concentrated in hypothalamic regions and peripheral tissues, modulate energy homeostasis, appetite regulation, and sexual function. MC2R mediates adrenal steroidogenesis, while MC5R influences exocrine gland function.

The structural modification that distinguishes Melanotan-1 from native alpha-MSH is a single amino acid substitution at position 9 (norleucine replacing methionine), which dramatically extends the peptide's half-life from minutes to hours by preventing enzymatic degradation. This substitution preserves the His-Phe-Arg-Trp sequence critical for MC1R binding while stabilizing the molecule against peptidase activity. Competitive radioligand binding assays published in the European Journal of Pharmacology demonstrate that Melanotan-1 exhibits binding affinity (Ki) of approximately 0.3 nM for MC1R, compared to 30–300 nM for MC3R and MC4R—a selectivity ratio of 100:1 to 1000:1 depending on assay conditions.

This receptor selectivity creates distinct melanotan-1 benefits for research protocols examining isolated melanogenesis pathways. Studies using Melanotan-2 must account for simultaneous activation of MC3R/MC4R, which introduces appetite suppression (mediated by hypothalamic POMC neuron activation), increased metabolic rate (through AMPK pathway modulation), and erectile function changes (via MC4R receptors in the spinal cord). Melanotan-1's minimal activity at these receptors allows researchers to attribute observed effects specifically to MC1R activation without the statistical complexity of multi-receptor confounding variables. Our discussions with research teams at Real Peptides consistently highlight this as the primary reason for selecting MT1 over MT2 in controlled melanogenesis studies.

The cAMP signaling cascade triggered by MC1R activation begins with Gs protein coupling, adenylyl cyclase activation, and subsequent cAMP accumulation. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). Phosphorylated CREB translocates to the nucleus and upregulates transcription of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte differentiation and melanogenesis. MITF in turn upregulates tyrosinase, TRP-1, and TRP-2—the enzymatic machinery that converts tyrosine to eumelanin through the DOPA and dopaquinone intermediates. This is the mechanism through which melanotan-1 benefits manifest as increased pigmentation in research models.

Photoprotection Mechanisms and UV-Independent Melanogenesis

Traditional melanogenesis induced by ultraviolet radiation operates through a damage-response pathway. UVB radiation (280–320 nm) causes direct DNA damage, particularly cyclobutane pyrimidine dimers and 6-4 photoproducts. Keratinocytes respond to this damage by upregulating p53, which induces POMC transcription and subsequent alpha-MSH secretion. The released alpha-MSH binds MC1R on adjacent melanocytes, triggering the cAMP-MITF-tyrosinase cascade described above. The resulting melanin is transferred to keratinocytes via dendritic melanocyte extensions, where melanin granules position themselves as a UV-absorbing cap over the nucleus—the biological basis of tanning as photoprotection.

Melanotan-1 bypasses the DNA damage requirement entirely. By providing exogenous MC1R stimulation, the peptide activates melanogenesis without requiring UV-induced keratinocyte signaling. Research published in Photochemistry and Photobiology demonstrated that melanocyte cultures treated with 100 nM Melanotan-1 showed tyrosinase activity increases of 380% within 72 hours, compared to 140% in UV-exposed controls and negligible change in untreated controls. The critical melanotan-1 benefits here are twofold: melanogenesis occurs before UV exposure, and the magnitude exceeds what UV alone produces.

The photoprotection conferred by pre-existing melanin is quantifiable through minimal erythema dose (MED) measurements—the UV exposure required to produce visible redness 24 hours post-exposure. Studies in fair-skinned volunteers (Fitzpatrick skin types I and II) using afamelanotide (the pharmaceutical formulation of Melanotan-1) reported MED increases of 2.0–2.8× baseline after 10–14 days of treatment. This means subjects who would normally burn after 20 minutes of midday sun exposure could tolerate 40–56 minutes at equivalent UV index before reaching the same erythema threshold. The melanin increase itself was measured through spectrophotometry, showing melanin index increases of 40–60% from baseline.

One melanocortin-1 benefits often overlooked in research design is the distinction between constitutive and facultative pigmentation. Constitutive pigmentation refers to baseline melanin production independent of UV exposure—what we commonly call "natural skin tone." Facultative pigmentation is the UV-induced increase above that baseline—what we call "tanning." Melanotan-1 increases both. The constitutive increase occurs through chronic MC1R stimulation upregulating baseline MITF expression, while the facultative increase occurs through enhanced melanocyte response to any UV exposure that does occur. In practical terms, research subjects begin darker and tan more efficiently from any given UV dose—a compounding effect relevant to photoprotection studies.

We've observed in our peptide preparation consultations that researchers sometimes conflate photoprotection with complete UV immunity, which is incorrect. Melanin absorbs and dissipates UV energy as heat, reducing but not eliminating DNA damage. Even with doubled MED thresholds, cumulative UV exposure still contributes to long-term photodamage and carcinogenesis risk. The melanin protection factor is roughly 1.5–3.0× depending on melanin density, meaning a 200% increase in exposure produces the same damage as baseline exposure would have—protection is proportional, not absolute.

Peptide Stability, Reconstitution Requirements, and Storage Protocols

Melanotan-1 is supplied as lyophilized powder—a freeze-dried crystalline solid formed by sublimation of water from a frozen peptide solution. This formulation extends shelf life dramatically compared to pre-mixed solutions. Unreconstituted lyophilized Melanotan-1 remains stable for 24–36 months when stored at −20°C, with degradation rates below 3% per year under proper conditions. Once reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water for injection), the peptide's stability decreases substantially. Reconstituted solutions stored at 2–8°C (standard refrigeration) maintain potency for 28–45 days, with degradation accelerating to approximately 2–5% per week after that window.

The critical melanotan-1 benefits are lost entirely if the peptide denatures during reconstitution or storage. Peptide denaturation refers to disruption of the secondary and tertiary structure—the specific three-dimensional folding that allows the peptide to bind its target receptor. For Melanotan-1, the His-Phe-Arg-Trp pharmacophore must maintain specific spatial orientation to fit the MC1R binding pocket. Temperature excursions above 25°C, pH shifts outside the 4.0–8.0 range, or mechanical agitation (vigorous shaking) can disrupt this structure. Denatured peptide retains its amino acid sequence but loses biological activity—it will not bind MC1R and therefore will not induce melanogenesis regardless of dose.

Reconstitution protocol matters more than most research teams realize. The correct procedure involves injecting bacteriostatic water slowly down the side of the vial, allowing it to run gently across the lyophilized powder rather than injecting directly onto the powder cake. Mechanical force from direct injection or vigorous shaking creates shear stress that can denature peptide bonds. After water addition, the vial should be rolled gently between palms or allowed to sit at room temperature for 5–10 minutes until the powder fully dissolves. The solution should be clear to slightly opalescent—any cloudiness or visible particulate indicates aggregation and potential denaturation.

Temperature management during shipping represents one of the highest-risk variables for peptide integrity loss. Unreconstituted lyophilized Melanotan-1 tolerates brief temperature excursions to room temperature (18–25°C) without significant degradation—typically 48–72 hours is safe. However, prolonged exposure above 30°C or any exposure above 40°C causes irreversible degradation. At Real Peptides, we use cold-chain shipping with temperature loggers for this reason. Reconstituted peptides are far less stable—any temperature excursion above 8°C for more than 4–6 hours begins measurable potency loss. Researchers traveling with reconstituted peptides must use insulin coolers or similar cold-storage systems that maintain 2–8°C continuously.

The pH of the reconstitution solvent also affects melanotan-1 benefits through stability mechanisms. Bacteriostatic water typically has a pH of 5.0–7.0, which is compatible with most peptides. Some researchers incorrectly use sterile saline (0.9% sodium chloride), which has a pH of 4.5–7.0 depending on manufacturer but lacks the bacteriostatic agent that prevents bacterial growth in multi-dose vials. Without benzyl alcohol, any contamination introduced during needle entry grows freely, creating infection risk and peptide degradation through bacterial protease activity. The benzyl alcohol in bacteriostatic water inhibits bacterial growth for 28 days, which is why it's the standard reconstitution solvent for multi-dose peptide vials.

Melanotan-1 Benefits: Research Comparison

Researchers selecting melanocortin peptides face a choice between Melanotan-1, Melanotan-2, and pharmaceutical afamelanotide (Scenesse). Each offers distinct pharmacological profiles and research applications. The table below compares receptor selectivity, half-life, typical research dosing, and primary study applications.

Peptide	MC1R Selectivity	Half-Life	Research Dose Range	Primary Study Application	Professional Assessment
Melanotan-1	100–1000× selective for MC1R over MC3R/MC4R	2.5–3.5 hours subcutaneous	0.5–2.0 mg/dose	Isolated melanogenesis studies, photoprotection mechanisms, MC1R binding assays	Best choice for studies requiring minimal confounding from appetite or metabolic effects—receptor selectivity allows attribution of effects specifically to MC1R pathway
Melanotan-2	10–20× selective for MC1R; significant MC3R/MC4R activity	1.5–2.5 hours subcutaneous	0.25–1.0 mg/dose	Multi-receptor melanocortin studies, appetite/energy regulation, combined metabolic-pigmentation research	Appropriate when simultaneous melanocortin pathway activation is desired, but introduces confounding variables if isolating MC1R effects is the goal
Afamelanotide (Scenesse)	Identical to Melanotan-1	2.0–3.0 hours; extended via implant formulation	16 mg implant (releases over 60 days)	Clinical photoprotection studies, erythropoietic protoporphyria research	Pharmaceutical-grade standardization with regulatory approval, but implant delivery system limits dose flexibility for controlled experiments

Melanotan-1 demonstrates the highest MC1R selectivity in competitive binding assays, making it the preferred choice when research protocols require isolation of MC1R-mediated effects from the broader melanocortin system. The distinction matters most in controlled mechanistic studies where appetite suppression or erectile function changes would confound interpretation of melanogenesis data.

What If: Melanotan-1 Research Scenarios

What If Reconstituted Melanotan-1 Was Left at Room Temperature Overnight?

Refrigerate immediately and discard if the temperature exceeded 25°C for more than 6–8 hours. Peptide stability at room temperature depends on duration and peak temperature—brief excursions (2–4 hours at 20–22°C) typically cause less than 10% potency loss, but overnight exposure (8–12 hours) can degrade 25–40% of active peptide. The challenge is that denaturation is not visible—the solution will appear unchanged even after significant potency loss. Researchers should treat any unrefrigerated reconstituted peptide as compromised and prepare a fresh vial rather than risk invalid study results from degraded material.

What If Melanogenesis Response in Research Models Is Lower Than Expected?

Verify peptide reconstitution date and storage temperature first—degraded peptide is the most common cause of suboptimal response. If the peptide was stored correctly, assess the baseline MC1R expression in your model system. Fair-skinned individuals with MC1R polymorphisms (particularly R151C, R160W, and D294H variants common in Fitzpatrick I/II skin types) show reduced receptor function, requiring 30–50% higher doses to achieve equivalent melanogenesis. The melanocortin-1 benefits depend entirely on functional MC1R expression—genetic screening of study subjects for common loss-of-function variants prevents confounding from low-response phenotypes.

What If You Need to Compare Melanotan-1 and Melanotan-2 in the Same Study?

Account for the 2–4× potency difference in melanogenesis induction—Melanotan-2 produces equivalent pigmentation at roughly half the molar dose of Melanotan-1 due to its higher intrinsic efficacy at MC1R despite similar binding affinity. More importantly, design protocols that either measure or control for MC3R/MC4R activation by MT2. This means tracking food intake if appetite suppression would confound results, or using subjects with matched metabolic baselines if energy expenditure changes matter. The cleaner experimental design is often to use Melanotan-1 for melanogenesis studies and Melanotan-2 only when multi-receptor activation is the intended variable—mixing them in a single study without controlling for off-target effects introduces unnecessary statistical noise.

What If Reconstituted Peptide Develops Visible Particles or Cloudiness?

Discard immediately—visible aggregation indicates denaturation or bacterial contamination, both of which eliminate peptide activity and introduce risk. Properly reconstituted Melanotan-1 should be clear to faintly opalescent. Cloudiness suggests protein aggregation from pH shift, temperature damage, or improper reconstitution technique. Particulate matter could be aggregated peptide, bacterial growth (if sterile technique was breached), or precipitated excipients. None of these should be injected into research subjects. Prevention requires strict adherence to reconstitution protocol: bacteriostatic water only, gentle mixing, immediate refrigeration, and sterile technique for every needle entry into the vial.

The Mechanistic Truth About Melanotan-1 Benefits

Here's the honest answer: Melanotan-1 doesn't "activate tanning genes" the way marketing materials suggest. It activates one specific receptor (MC1R), which triggers one specific transcription factor (MITF), which upregulates three specific enzymes (tyrosinase, TRP-1, TRP-2). The melanogenesis pathway is linear and well-characterized—there's no mysterious "enhanced tanning" beyond what that enzymatic cascade produces. The melanotan-1 benefits are real, substantial, and reproducible, but they're mechanistic, not metabolic magic.

The photoprotection is meaningful but proportional. Doubling melanin density doesn't halve DNA damage—it reduces it by approximately 40–60% depending on UV wavelength and melanin type (eumelanin vs pheomelanin). Research teams sometimes overstate the protective effect, particularly when comparing fair-skinned baseline to post-treatment pigmentation. A Fitzpatrick I individual who reaches Fitzpatrick III pigmentation through Melanotan-1 has improved photoprotection compared to their baseline, but they have not achieved the photoprotection of a constitutively Fitzpatrick V individual—melanin density matters, but so does melanin distribution, keratinocyte transfer efficiency, and basal antioxidant capacity.

The selectivity for MC1R over MC3R/MC4R is the actual differentiator between Melanotan-1 and Melanotan-2 in research contexts. This isn't subjective—it's measurable in competitive binding assays with radiolabeled ligands. The 100–1000× selectivity ratio means that at doses producing equivalent melanogenesis, Melanotan-1 occupies 10–100× fewer MC3R and MC4R receptors than Melanotan-2. For researchers designing controlled studies, that distinction is the difference between clean data and confounded results. The melanocortin-1 benefits aren't "better" than MT2 in an absolute sense—they're more specific, which is what matters in mechanistic research.

Let's be direct about peptide stability: most preparation errors that compromise results happen during reconstitution or storage, not during synthesis or shipping. We've reviewed hundreds of research protocols at Real Peptides, and the pattern is consistent—studies with anomalous results trace back to temperature excursions, incorrect reconstitution solvents, or expired bacteriostatic water far more often than to peptide purity issues. The lyophilized powder is remarkably stable; the reconstituted solution is fragile. That 28-day refrigerated stability window isn't conservative—it's the validated degradation threshold from HPLC stability studies. Using peptide beyond that window means dosing uncertainty, which invalidates quantitative research.

The structural simplicity of Melanotan-1—a 13-amino-acid peptide with one substitution from native alpha-MSH—is both strength and limitation. The strength is that the mechanism is fully characterized; there are no unknown metabolites or off-target binding sites being discovered years after initial research. The limitation is that the peptide does one thing well (MC1R activation) and nothing else. Researchers seeking multi-target melanocortin effects need different tools. That specificity is precisely why Melanotan-1 remains the reference standard for isolated melanogenesis studies despite being one of the earliest synthetic melanocortin analogs developed.

Melanotan-1 represents decades of melanocortin pharmacology distilled into a single stable, selective, well-characterized research tool. The benefits are mechanistic precision, not pharmacological versatility. Research protocols designed around that precision generate cleaner data than those treating it as a general-purpose melanocortin agonist. At Real Peptides, our commitment to small-batch synthesis with exact amino-acid sequencing ensures that every vial of Melanotan 1 delivers the receptor selectivity and peptide purity that controlled mechanistic studies require. For researchers exploring broader peptide applications, our full peptide collection extends that same synthesis precision across melanocortin analogs, metabolic research compounds, and neuropeptide tools—each manufactured to the same purity and consistency standards that make quantitative peptide research possible.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-1 demonstrates 100–1000× selectivity for MC1R over MC3R and MC4R in competitive binding assays, while Melanotan-2 shows only 10–20× selectivity. This means MT1 activates melanogenesis pathways with minimal appetite suppression, metabolic rate changes, or erectile function effects—all of which occur with MT2 through its significant MC3R and MC4R activity. For research protocols isolating MC1R-mediated melanogenesis from broader melanocortin system effects, Melanotan-1 eliminates confounding variables that MT2 introduces. The structural difference is subtle but the pharmacological consequence is substantial for controlled studies.

Melanotan-1 binds MC1R on melanocyte cell surfaces, triggering Gs protein coupling and adenylyl cyclase activation. The resulting cAMP accumulation activates protein kinase A (PKA), which phosphorylates CREB. Phosphorylated CREB upregulates MITF (microphthalmia-associated transcription factor), the master regulator that induces transcription of tyrosinase, TRP-1, and TRP-2—the enzymatic machinery converting tyrosine to eumelanin. This pathway bypasses the UV-damage requirement for normal melanogenesis, producing pigmentation without requiring DNA damage-induced keratinocyte signaling. Studies show this process increases melanin synthesis 300–500% above baseline UV-stimulated levels.

Reconstituted Melanotan-1 stored at 2–8°C in bacteriostatic water maintains greater than 95% potency for 28–45 days based on HPLC stability assays. Beyond that window, degradation accelerates to approximately 2–5% per week. Temperature excursions above 8°C dramatically reduce stability—exposure to room temperature (20–25°C) for 6–8 hours can cause 10–25% potency loss. Unreconstituted lyophilized powder is far more stable, remaining viable for 24–36 months at −20°C with less than 3% annual degradation. Researchers should prepare only the volume needed for 3–4 weeks of studies rather than reconstituting entire vials for long-term storage.

Yes, Melanotan-1 induces melanogenesis independent of UV exposure by providing direct MC1R stimulation that bypasses the DNA damage-keratinocyte-alpha-MSH pathway required for UV-induced tanning. Melanocyte cultures treated with 100 nM Melanotan-1 show 380% increases in tyrosinase activity within 72 hours without any UV exposure, compared to 140% in UV-exposed controls. In research subjects, this produces baseline pigmentation increase before any sun exposure occurs, and the pre-existing melanin provides photoprotection measured as 2.0–2.8× increases in minimal erythema dose. The melanin deposited in keratinocytes absorbs and dissipates UV energy as heat, reducing DNA damage proportionally to melanin density.

The most common error is vigorous shaking during reconstitution, which creates shear stress that denatures peptide structure and eliminates MC1R binding activity. Correct technique involves injecting bacteriostatic water slowly down the vial side and rolling gently or allowing passive dissolution. The second most common error is using sterile saline instead of bacteriostatic water, which lacks benzyl alcohol to prevent bacterial growth in multi-dose vials. Third is temperature management failure—storing reconstituted peptide at room temperature or in non-refrigerated areas causes cumulative degradation that is invisible but eliminates biological activity. Finally, using peptide beyond the 28–45 day refrigerated stability window introduces dose uncertainty that invalidates quantitative studies.

MC1R polymorphisms, particularly R151C, R160W, and D294H variants common in fair-skinned populations, reduce receptor function and melanogenesis response to Melanotan-1. Individuals carrying loss-of-function MC1R variants require 30–50% higher peptide doses to achieve equivalent melanin production compared to wild-type MC1R subjects. This creates dose-response heterogeneity in research populations unless genetic screening identifies and stratifies subjects by MC1R genotype. The practical consequence is that studies using outbred populations with mixed MC1R genetics show higher response variance than those using genetically characterized models. Screening for common MC1R variants prevents misattribution of low response to peptide quality issues when the cause is genetic receptor function.

Constitutive pigmentation is baseline melanin production independent of UV exposure—your natural skin tone. Facultative pigmentation is the UV-induced increase above that baseline—what we call tanning. Melanotan-1 increases both through distinct mechanisms: constitutive pigmentation rises through chronic MC1R stimulation upregulating baseline MITF expression, while facultative pigmentation increases through enhanced melanocyte response to any UV exposure that occurs. In research terms, subjects begin with higher baseline melanin density and tan more efficiently from any given UV dose—a compounding effect measured as both elevated melanin index at baseline and steeper dose-response curves to controlled UV exposure.

Native alpha-MSH has a plasma half-life of only 3–7 minutes because peptidases rapidly cleave the Met-Glu-His-Phe sequence. Melanotan-1 substitutes norleucine for methionine at position 9, creating a structure resistant to enzymatic degradation while preserving the His-Phe-Arg-Trp pharmacophore required for MC1R binding. This single amino acid change extends the half-life to 2.5–3.5 hours—a 20–60× increase that allows practical dosing intervals for research protocols. The norleucine substitution is chemically subtle (replacing a sulfur-containing side chain with an aliphatic hydrocarbon) but pharmacokinetically transformative, converting an endogenous hormone with minute-scale duration into a research tool with hour-scale activity.

The melanin produced through MC1R activation by Melanotan-1 is chemically identical to UV-induced melanin—both are eumelanin synthesized through the tyrosinase-DOPA-dopaquinone pathway. The photoprotective capacity depends on melanin density, distribution, and type, not the stimulus that triggered production. The advantage of Melanotan-1-induced melanin is that it forms before UV exposure occurs, providing protection during initial sun exposure rather than after DNA damage has already accumulated. Studies measuring minimal erythema dose show equivalent photoprotection per unit melanin density whether induced by UV or by MC1R agonist, but Melanotan-1 achieves higher peak melanin levels (40–60% increases) than typical UV exposure produces in fair-skinned individuals.

Lyophilized Melanotan-1 should be stored at −20°C in the original sealed vial with desiccant to prevent moisture absorption. At this temperature, the peptide remains stable for 24–36 months with less than 3% degradation. Short-term storage at 2–8°C (standard refrigeration) is acceptable for up to 6 months, though stability decreases to 12–18 months with approximately 5% annual degradation. Room temperature storage (20–25°C) should be limited to shipping duration only—prolonged exposure beyond 48–72 hours begins measurable potency loss. Any exposure above 30°C accelerates degradation dramatically, and temperatures above 40°C cause irreversible denaturation. The powder's crystalline structure protects the peptide, but moisture and heat are the primary degradation vectors for lyophilized formulations.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA